• Annual Report 2020

    Following a good start to the year, Medistim experienced a significant impact on operations in the first months of the pandemic. However, due to a solid revenue base and good pipeline activity throughout the second…

    Read more
  • Results for the Fourth Quarter and Preliminary Results for 2020

    Sales for the quarter ended at MNOK 94.2 (MNOK 95.7), a decrease of 1.6%. Sales for 2020 ended at MNOK 363.1 (MNOK 363.7). Operating result (EBIT) for the quarter ended at MNOK 22.1 (MNOK 19.7)…

    Read more
  • Webinar: Q4 2020 presentation

    Sign up for the upcoming financial report presentation. You're invited to join this online presentation on Friday 26 February at 8 AM CET. CEO Kari E. Krogstad and CFO Thomas Jakobsen will present the fourth…

    Read more
  • Medistim partners with LivaNova as their new distributor for India

    With its population size of about 1,4 billion, India is a large and emerging market for Medistim’s ultrasound devices.  Today, about 100,000 coronary bypass (CABG) procedures are performed in India annually, representing a market size…

    Read more
  • Results for the Third Quarter 2020

    Sales for the quarter ended at MNOK 83.4 (MNOK 85.5), a decrease of 2,5%. Read the full report and presentation below. Q3 report 2020 Q3 presentation 2020

    Read more
  • Webinar: Third Quarter Financial Results

    Sign up for the upcoming financial report presentation. You're invited to join this presentation on Thursday 22 October at 8 AM CEST. CEO Kari E. Krogstad and CFO Thomas Jakobsen will present the third quarter results,…

    Read more
  • Results for the Second Quarter and First Half 2020

    Sales for the quarter ended at MNOK 82.5 (MNOK 93.8), a decrease of 12.2%. Sales for the 1st half ended at MNOK 185.6 (MNOK 182.5), a 1.7 % increase. Read the full report and presentation…

    Read more
  • Webinar: Second Quarter and Half-yearly Financial Report

    Sign up for the upcoming financial report presentation. You're invited to join this presentation on Friday 14 August at 8 AM CEST. CEO Kari E. Krogstad and CFO Thomas Jakobsen will present the second quarter and…

    Read more
  • Results for the First Quarter 2020

    Sales for the quarter ended at a record high MNOK 103.1 (MNOK 88.7), a 16.2% increase.This was driven by strong growth in capital sales of systems in Japan after regulatory approval of MiraQ™. Read the…

    Read more
  • Annual Report 2019

    We have now achieved a market penetration of 23% in USA, measured as the share of bypass procedures done with Medistim’s devices. Our position in Asia and Europe is also strengthened, through increased sales and…

    Read more